Cover	12 Months Ended
Cover	Dec. 31, 2025
Document Information [Line Items]
Document Type	DEF 14A
Amendment Flag	false
Entity Information [Line Items]
Entity Registrant Name	Tenet Healthcare Corporation
Entity Central Index Key	0000070318

Pay vs Performance Disclosure - USD ($)

4 Months Ended

8 Months Ended

12 Months Ended

Dec. 31, 2021

Aug. 31, 2021

Dec. 31, 2025

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Pay vs Performance Disclosure

Pay vs Performance Disclosure, Table

Pay Versus Performance

In accordance with SEC rules, we provide the following disclosure regarding executive compensation and Company performance for the fiscal years listed below. The HR Committee did not consider this pay versus performance disclosure or the “compensation actually paid” amounts below in making its pay decisions for any of the fiscal years shown.



										Average Summary Compensation		Average		Value of Initial Fixed $100 Investment (3)
Year	Summary Compensation Table Total for Dr. Sutaria ($) (1)		Summary Compensation Table Total for Mr. Rittenmeyer ($) (1)		Compensation Actually Paid to Dr. Sutaria ($) (1)(2)			Compensation Actually Paid to Mr. Rittenmeyer ($) (1)(2)		Table Total for Non-PEO NEOs ($) (1)		Compensation Actually Paid to Non-PEO NEOs ($) (1)(2)		Company TSR ($)		Peer Group TSR ($)		Net Income ($MM) (4)		Adjusted EBITDA ($MM) (5)

2025		43,108,969		—		149,381,157			—		7,765,674		15,831,784		497.67		148.36		2,367		4,566

2024		24,661,553		—		88,894,676			—		4,764,010		11,098,143		316.13		129.46		4,064		3,995

2023		18,518,109		—		63,876,884			—		4,661,937		9,805,274		189.26		126.21		1,311		3,541

2022		11,047,128		—		(9,106,588	)		—		6,921,122		1,325,894		122.19		123.67		1,001		3,469

2021		21,153,672		18,666,160		50,394,322			34,148,681		4,786,880		11,458,403		204.58		126.13		1,476		3,483

(1)

Ron Rittenmeyer served as our principal executive officer (PEO) during 2021 until he was succeeded by Dr. Sutaria on September 1, 2021, who served as our PEO for the remainder of 2021 and for 2022 through 2025. The

Non-PEO

NEOs for whom the average compensation is presented in this table are: (i) for fiscal 2024 and 2025, Messrs. Park and Arnst and Mses. Arbour and Foo; (ii) for fiscal 2023, Mr. Arnst, Mses. Arbour and Foo, and Dan Cancelmi, our former Executive Vice President and Chief Financial Officer; (iii) for fiscal 2022, Messrs. Rittenmeyer, Cancelmi and Arnst and Mses. Arbour and Foo; and (iv) for fiscal 2021, Messrs. Cancelmi and Arnst, Ms. Arbour and Audrey Andrews, our former Executive Vice President and General Counsel.

(2)

The amounts shown as Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation

S-K

and do not reflect the total compensation actually realized or received by the Company’s NEOs. In accordance with these rules, these amounts reflect total compensation as set forth in the Summary Compensation Table for each year, adjusted as shown below. Equity values are calculated in accordance with FASB ASC Topic 718, and the valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of the grant.



Compensation Actually Paid	Dr. Sutaria 2025		Average Non- PEO NEOs 2025

Summary Compensation Table Total		43,108,969		7,765,674

Less, value of Stock Awards and Option Awards reported in Summary Compensation Table		(31,677,365)		(2,809,783)

Plus, year-end fair value of outstanding and unvested equity awards granted in the year		88,979,631		6,056,338

Plus, year-over-year change in fair value of outstanding and unvested equity awards granted in prior years		39,911,004		4,531,009

Plus, fair value as of the vesting date of equity awards granted and vested in the year		2,586,540		—

Plus, change in fair value from prior year-end to vesting date of equity awards granted in prior years that vested in the year		6,472,378		288,546

Compensation Actually Paid		149,381,157		15,831,784

(3)

Amounts in these columns assume $100 was invested for the cumulative period from December 31, 2020 through the end of the listed fiscal year, in either the Company’s common stock or the S&P 500 Health Care Index (the Company’s peer group), as applicable, and reinvestment of the

pre-tax

value of dividends paid. Historical stock performance is not necessarily indicative of future stock performance.

(4)	Reflects the Company’s net income, as reported in the Company’s Annual Report on Form 10-K for each of Fiscal Years 2025, 2024, 2023, 2022 and 2021.

(5)

We determined Adjusted EBITDA to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEO and other NEOs in 2025, 2024 and 2023. This performance measure may not have been the most important financial performance measure for prior fiscal years, and we may determine a different financial performance measure to be the most important measure in future years. Adjusted EBITDA, a

non-GAAP

measure, is defined in Appendix A, and reconciliations of this

non-GAAP

financial measure to the most directly comparable GAAP measure may be found in the Company’s Annual Report on Form

10-K

for each of Fiscal Years 2025, 2024, 2023, 2022 and 2021.

Company Selected Measure Name

Adjusted EBITDA

Named Executive Officers, Footnote

Non-PEO

Peer Group Issuers, Footnote

pre-tax

value of dividends paid. Historical stock performance is not necessarily indicative of future stock performance.

Adjustment To PEO Compensation, Footnote



Compensation Actually Paid	Dr. Sutaria 2025		Average Non- PEO NEOs 2025

Summary Compensation Table Total		43,108,969		7,765,674

Less, value of Stock Awards and Option Awards reported in Summary Compensation Table		(31,677,365)		(2,809,783)

Plus, year-end fair value of outstanding and unvested equity awards granted in the year		88,979,631		6,056,338

Plus, year-over-year change in fair value of outstanding and unvested equity awards granted in prior years		39,911,004		4,531,009

Plus, fair value as of the vesting date of equity awards granted and vested in the year		2,586,540		—

Plus, change in fair value from prior year-end to vesting date of equity awards granted in prior years that vested in the year		6,472,378		288,546

Compensation Actually Paid		149,381,157		15,831,784

Non-PEO NEO Average Total Compensation Amount

$ 7,765,674

$ 4,764,010

$ 4,661,937

$ 6,921,122

$ 4,786,880

Non-PEO NEO Average Compensation Actually Paid Amount

$ 15,831,784

11,098,143

9,805,274

1,325,894

11,458,403

Adjustment to Non-PEO NEO Compensation Footnote



Compensation Actually Paid	Dr. Sutaria 2025		Average Non- PEO NEOs 2025

Summary Compensation Table Total		43,108,969		7,765,674

Less, value of Stock Awards and Option Awards reported in Summary Compensation Table		(31,677,365)		(2,809,783)

Plus, year-end fair value of outstanding and unvested equity awards granted in the year		88,979,631		6,056,338

Plus, year-over-year change in fair value of outstanding and unvested equity awards granted in prior years		39,911,004		4,531,009

Plus, fair value as of the vesting date of equity awards granted and vested in the year		2,586,540		—

Plus, change in fair value from prior year-end to vesting date of equity awards granted in prior years that vested in the year		6,472,378		288,546

Compensation Actually Paid		149,381,157		15,831,784

Compensation Actually Paid vs. Total Shareholder Return

Company vs Peer Group TSR and Compensation Actually Paid vs Company TSR

Compensation Actually Paid vs. Net Income

Compensation Actually Paid vs Net Income

Compensation Actually Paid vs. Company Selected Measure

Compensation Actually Paid vs Adjusted EBITDA

Total Shareholder Return Vs Peer Group

Company vs Peer Group TSR and Compensation Actually Paid vs Company TSR

Tabular List, Table

Financial Performance Measures

The following list presents the financial performance measures that the Company has determined represent the most important in linking “Compensation Actually Paid” to our PEO and the other NEOs for 2025 to Company performance. These measures are not ranked.

•

Adjusted EBITDA;

•

Adjusted Free Cash Flow less cash distributions paid to noncontrolling interests as reflected on the Company’s consolidated statements of cash flows; and

•

Adjusted EPS.

Total Shareholder Return Amount

$ 497.67

316.13

189.26

122.19

204.58

Peer Group Total Shareholder Return Amount

148.36

129.46

126.21

123.67

126.13

Net Income (Loss)

$ 2,367,000,000

$ 4,064,000,000

$ 1,311,000,000

$ 1,001,000,000

$ 1,476,000,000

Company Selected Measure Amount

4,566,000,000

3,995,000,000

3,541,000,000

3,469,000,000

3,483,000,000

Measure:: 1

Pay vs Performance Disclosure

Name

Adjusted EBITDA

Non-GAAP Measure Description

Adjusted EBITDA, a

non-GAAP

measure, is defined in Appendix A, and reconciliations of this

non-GAAP

financial measure to the most directly comparable GAAP measure may be found in the Company’s Annual Report on Form

10-K

for each of Fiscal Years 2025, 2024, 2023, 2022 and 2021.

Measure:: 2

Pay vs Performance Disclosure

Name

Adjusted Free Cash Flow less cash distributions paid to noncontrolling interests as reflected on the Company’s consolidated statements of cash flows

Measure:: 3

Pay vs Performance Disclosure

Name

Adjusted EPS

Dr. Sutaria [Member]

Pay vs Performance Disclosure

PEO Total Compensation Amount

$ 43,108,969

$ 24,661,553

$ 18,518,109

$ 11,047,128

$ 21,153,672

PEO Actually Paid Compensation Amount

$ 149,381,157

$ 88,894,676

$ 63,876,884

$ (9,106,588)

50,394,322

PEO Name

Dr. Sutaria

Mr. Rittenmeyer [Member]

Pay vs Performance Disclosure

PEO Total Compensation Amount

18,666,160

PEO Actually Paid Compensation Amount

$ 34,148,681

PEO Name

Ron Rittenmeyer

PEO | Dr. Sutaria [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

$ (31,677,365)

PEO | Dr. Sutaria [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

88,979,631

PEO | Dr. Sutaria [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

39,911,004

PEO | Dr. Sutaria [Member] | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

2,586,540

PEO | Dr. Sutaria [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

6,472,378

Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(2,809,783)

Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

6,056,338

Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

4,531,009

Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

$ 288,546

Award Timing Disclosure	12 Months Ended
Award Timing Disclosure	Dec. 31, 2025
Award Timing Disclosures [Line Items]
Award Timing MNPI Disclosure	Equity Grant Timing and Stock Option Exercise Prices Historically, we have made annual equity awards to NEOs and other employees during the first quarter of the year in connection with annual executive compensation decisions. In accordance with the terms of our equity plans, the grant date of these awards is the date the HR Committee approves the grant, which usually occurs at a meeting scheduled more than one year in advance. We may occasionally grant equity awards to newly hired employees, employees who have been promoted, or for special recognition, retention or other purposes outside of the annual grant process. For equity grants awarded outside of the annual grant cycle, the grant date generally is the first or 15th day of the month following hire or approval (or, if such date is not a trading day, the following date that is a trading day), subject to the HR Committee’s discretion in extraordinary circumstances. The exercise price for all stock options generally equals (and will be no less than) the NYSE closing price per share of our common stock on the date of grant or on the immediately preceding trading day if the date of grant is not a trading day. No stock options were granted during 2025. HR Committee approval is required in all cases where the recipient of an equity grant is a NEO or other senior officer. The HR Committee did not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation in 2025.
Award Timing Method	We may occasionally grant equity awards to newly hired employees, employees who have been promoted, or for special recognition, retention or other purposes outside of the annual grant process. For equity grants awarded outside of the annual grant cycle, the grant date generally is the first or 15th day of the month following hire or approval (or, if such date is not a trading day, the following date that is a trading day), subject to the HR Committee’s discretion in extraordinary circumstances. The exercise price for all stock options generally equals (and will be no less than) the NYSE closing price per share of our common stock on the date of grant or on the immediately preceding trading day if the date of grant is not a trading day. No stock options were granted during 2025.
Award Timing MNPI Considered	true
MNPI Disclosure Timed for Compensation Value	true

Insider Trading Policies and Procedures	12 Months Ended
Insider Trading Policies and Procedures	Dec. 31, 2025
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true